Vizient has ranked Rush University Medical Center #1 for quality among the nation’s most prestigious academic medical centers. Learn more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study of Intracranial Dural Arteriovenous Fistulas

Clinical Trial Title: 
PHIL dAVF: Study of Phill® Embolic System in the treatment of intracranial dural arteriovenous fistulas.
Clinical Trial Protocol ID: 
17111006
Clinical Trial Investigator Name: 
Michael Chen, MD
Clinical Trial Protocol Description: 

This study is a prospective, multicenter, single-arm study. Patients with dural arteriovenous fistulas (dAVF) have a few choices for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 22 and 80 years of age.
  • Are willing and capable of complying with all study protocol requirements, including specified follow-up period.
  • Provide written informed consent (subject or authorized legal representative) prior to initiation of any study procedures.
  • Have an intracranial dAVF.

You will be excluded from the study if any of the following criteria apply to you:

  • Have multiple dAVFs to be treated.
  • Have a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated).
  • Have known allergies to dimethylsulfoxide, iodine.
  • Are currently participating in another clinical study

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Stroke and Cerebrovascular Disease
Contact Phone: 
(312) 942-8681
Contact Name: 
Kevin Keegan